Dynamics of serum concentrations of antibodies to infliximab: a new approach for predicting secondary loss of response in inflammatory bowel diseases

Antibodies to infliximab (ATI) in serum are related to secondary lack of response (LOR) to infliximab (IFX) remedy in sufferers with inflammatory bowel illness (IBD).

by Frank Rivera7 Min Reading